AR1001 Polypharmacology: Improving Cerebral Perfusion, Inducing Neuroprotection, Enhancing Synaptic Plasticity & Preventing Tau Phosphorylation via PDE5 Inhibition

• Demonstrating how AR1001 induces multiple neuroprotective effects, with potential to be disease-modifying
• Investigating the commercial and clinical variability of AR1001 under POLARIS-AD (global Phase III trial)
• Showing how AR1001 achieves simultaneous multimodal effects while maintaining an exceptional safety profile

Speakers:

Jae-Young Ha

Senior Vice President

AriBio